2026-10-14T20:48:18Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33952189 2026-09-30T13:59:02Z category_67901 category_67907 portal_1154 item_type_5 month_year_09_2026

Congress poster: IMS 2026 Expert-defined thresholds for meaningful between-group differences in vasomotor symptom and sleep disturbance trial endpoints (poster 107) Rossella E. Nappi (2744353) Andrew Trigg (3968021) Marcelo Graziano Custodio (18990942) James A. Simon (13763258) Petra Stute (11659384) Nils Schoof (190380) Stephane Deparis (25137641) Tommi Tervonen (5298976) Claudio N. Soares (11037515) Menopause Sleep MIDNIGHT IMS 2026 <p dir="ltr">Poster presented at IMS 2026 to communicate results from the MIDNIGHT study. Experts identified meaningful between-group differences for measures of VMS frequency/severity and sleep disturbances that indicate clinically relevant treatment effects. These findings support the interpretation of clinical trial data for neurokinin-targeted therapies, such as elinzanetant, in relation to menopause symptom endpoints.</p> 2026-09-30T13:59:02Z Image Poster 10.71943/bayer.figshare.33952189.v1 https://figshare.com/articles/poster/Congress_poster_IMS_2026_Expert-defined_thresholds_for_meaningful_between-group_differences_in_vasomotor_symptom_and_sleep_disturbance_trial_endpoints_poster_107_/33952189 CC BY-ND